ZA200904436B - Modified release ibuprofen solid oral dosage form - Google Patents

Modified release ibuprofen solid oral dosage form

Info

Publication number
ZA200904436B
ZA200904436B ZA200904436A ZA200904436A ZA200904436B ZA 200904436 B ZA200904436 B ZA 200904436B ZA 200904436 A ZA200904436 A ZA 200904436A ZA 200904436 A ZA200904436 A ZA 200904436A ZA 200904436 B ZA200904436 B ZA 200904436B
Authority
ZA
South Africa
Prior art keywords
dosage form
oral dosage
modified release
solid oral
release ibuprofen
Prior art date
Application number
ZA200904436A
Other languages
English (en)
Inventor
Michael Hite
Cathy Federici
Alan Brunelle
Stephen Turner
Original Assignee
Scolr Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scolr Pharma Inc filed Critical Scolr Pharma Inc
Publication of ZA200904436B publication Critical patent/ZA200904436B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
ZA200904436A 2006-12-04 2009-06-25 Modified release ibuprofen solid oral dosage form ZA200904436B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/633,322 US20070077297A1 (en) 2004-09-30 2006-12-04 Modified release ibuprofen dosage form

Publications (1)

Publication Number Publication Date
ZA200904436B true ZA200904436B (en) 2010-04-28

Family

ID=39476091

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200904436A ZA200904436B (en) 2006-12-04 2009-06-25 Modified release ibuprofen solid oral dosage form

Country Status (14)

Country Link
US (3) US20070077297A1 (zh)
EP (1) EP2099433A2 (zh)
JP (1) JP2010511614A (zh)
KR (1) KR20090086468A (zh)
CN (2) CN101588793B (zh)
AU (1) AU2007328393A1 (zh)
BR (1) BRPI0717916A8 (zh)
CA (1) CA2670887A1 (zh)
CO (1) CO6190599A2 (zh)
IL (1) IL199191A0 (zh)
MX (1) MX2009005958A (zh)
TW (1) TW200831135A (zh)
WO (1) WO2008069941A2 (zh)
ZA (1) ZA200904436B (zh)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
US20060068009A1 (en) * 2004-09-30 2006-03-30 Scolr Pharma, Inc. Modified release ibuprofen dosage form
US20070077297A1 (en) * 2004-09-30 2007-04-05 Scolr Pharma, Inc. Modified release ibuprofen dosage form
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US7749537B2 (en) * 2006-12-04 2010-07-06 Scolr Pharma, Inc. Method of forming a tablet
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
WO2009010238A2 (en) * 2007-07-13 2009-01-22 Synthon B.V. Duloxetine formulations
CA2713128C (en) 2008-01-25 2016-04-05 Gruenenthal Gmbh Pharmaceutical dosage form
KR101690094B1 (ko) 2008-05-09 2016-12-27 그뤼넨탈 게엠베하 분무 응결 단계의 사용하에 중간 분말 제형 및 최종 고체 제형을 제조하는 방법
AR076907A1 (es) * 2009-05-13 2011-07-20 Wyeth Llc Composiciones con liberacion rapida de farmaco
NZ596667A (en) 2009-07-22 2013-09-27 Gruenenthal Chemie Hot-melt extruded controlled release dosage form
BR112012001466A2 (pt) 2009-07-22 2020-08-11 Grünenthal GmbH forma de dosagem resistente à falsificação para opioides sensíveis à oxidação, seu processo de fabricação, e embalagem
PE20131126A1 (es) 2010-09-02 2013-10-21 Gruenenthal Chemie Forma de dosificacion resistente a alteracion que comprende un polimero anionico
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
WO2012116434A1 (en) * 2011-03-01 2012-09-07 4413261 Canada Inc. (Spencer Canada) Two speed monolithic system for controlled release of drugs
MX348054B (es) 2011-07-29 2017-05-25 Gruenenthal Gmbh Tableta a prueba de alteracion que proporciona liberacion inmediata del farmaco.
CA2839123A1 (en) 2011-07-29 2013-02-07 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
PT2594266E (pt) * 2011-11-17 2014-11-03 Zambon Spa Composições farmacêuticas sólidas que contêm sais de ibuprofeno
EP2819656A1 (en) 2012-02-28 2015-01-07 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
SI2838512T1 (sl) 2012-04-18 2018-11-30 Gruenenthal Gmbh Pred posegi in prehitrim sproščanjem odporna farmacevtska oblika odmerka
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CA2913209A1 (en) 2013-05-29 2014-12-04 Grunenthal Gmbh Tamper resistant dosage form with bimodal release profile
US10154966B2 (en) 2013-05-29 2018-12-18 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
KR20160031526A (ko) 2013-07-12 2016-03-22 그뤼넨탈 게엠베하 에틸렌-비닐 아세테이트 중합체를 함유하는 템퍼 내성 투여형
BR112016010482B1 (pt) 2013-11-26 2022-11-16 Grünenthal GmbH Preparação de uma composição farmacêutica em pó por meio de criomoagem
JP6440317B2 (ja) * 2014-04-17 2018-12-19 ライオン株式会社 内服固形錠剤
CN106572980A (zh) 2014-05-12 2017-04-19 格吕伦塔尔有限公司 包含他喷他多的防篡改即释胶囊制剂
EP3148512A1 (en) 2014-05-26 2017-04-05 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
JP6180382B2 (ja) * 2014-07-30 2017-08-16 ライオン株式会社 錠剤及びその製造方法
US20170252452A1 (en) * 2014-08-28 2017-09-07 Sanofi-Aventis Deutschland Gmbh Film coated tablet for the treatment of acute pain
CN104258411A (zh) * 2014-09-19 2015-01-07 安徽山河药用辅料股份有限公司 一种硅化微晶纤维素复合辅料及其制备方法
CA2983642A1 (en) 2015-04-24 2016-10-27 Grunenthal Gmbh Tamper-resistant dosage form with immediate release and resistance against solvent extraction
US10842750B2 (en) 2015-09-10 2020-11-24 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
AU2022201576A1 (en) * 2022-03-08 2023-09-28 Aft Pharmaceuticals Limited Medication

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4097606A (en) * 1975-10-08 1978-06-27 Bristol-Myers Company APAP Tablet containing an alkali metal carboxymethylated starch and processes for manufacturing same
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4609675A (en) * 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
GB8601204D0 (en) * 1986-01-18 1986-02-19 Boots Co Plc Therapeutic agents
US4888343A (en) * 1986-09-15 1989-12-19 Bristol-Myers Company Pharmaceutical compositions for relief of dysmenorrhea and/or premenstrual syndrome and process
DE3639038C2 (de) * 1986-11-14 1997-02-06 Helmut Dr Lukas Verwendung von S-(+)-Ibuprofen zur schnellen Behandlung humaner Schmerzen
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US5200193A (en) * 1987-04-22 1993-04-06 Mcneilab, Inc. Pharmaceutical sustained release matrix and process
US4806359A (en) 1987-04-22 1989-02-21 Mcneilab, Inc. Iburprofen sustained release matrix and process
EP0297866A3 (en) 1987-07-01 1989-12-13 The Boots Company PLC Therapeutic agents
SE463541B (sv) * 1987-08-31 1990-12-10 Lejus Medical Ab Granulaer produkt oeverdragen av en smaelta av sig sjaelv samt foerfarande foer dess framstaellning
US4814181A (en) * 1987-09-03 1989-03-21 Alza Corporation Dosage form comprising fast agent delivery followed by slow agent delivery
US4916161A (en) * 1988-10-25 1990-04-10 Bristol-Myers Squibb Taste-masking pharmaceutical agents
US5104648A (en) * 1989-02-02 1992-04-14 Mallinckrodt Specialty Chemicals Company High ibuprofen content granulations
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
US5009895A (en) * 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
US5087454A (en) * 1990-07-30 1992-02-11 American Home Products Corporation Ibuprofen tablet
JPH069382A (ja) * 1992-04-17 1994-01-18 Takeda Chem Ind Ltd 安定化された固型製剤およびその製造方法
US5429825A (en) * 1992-06-26 1995-07-04 Mcneil-Ppc, Inc. Rotomelt granulation
US5512300A (en) * 1992-09-15 1996-04-30 Warner-Lambert Company Prevention of ibuprofen from forming low melting eutectics with other therapeutic agents in solid dosage forms
US5482718A (en) * 1994-03-23 1996-01-09 Hoffmann-La Roche Inc. Colon-targeted delivery system
DE4444051A1 (de) * 1994-12-10 1996-06-13 Rhone Poulenc Rorer Gmbh Pharmazeutische, oral anwendbare Zubereitung
GB9603699D0 (en) 1996-02-21 1996-04-17 Boots Co Plc Therapeutic composition
US6348216B1 (en) * 1996-06-10 2002-02-19 Knoll Pharmaceutical Company Ibuprofen and narcotic analgesic compositions
US6361794B1 (en) * 1996-06-12 2002-03-26 Basf Corporation Method of making ibuprofen and narcotic analgesic composition
US5830503A (en) * 1996-06-21 1998-11-03 Andrx Pharmaceuticals, Inc. Enteric coated diltiazem once-a-day formulation
WO1998001117A1 (en) * 1996-07-08 1998-01-15 Edward Mendell Co., Inc. Sustained release matrix for high-dose insoluble drugs
GB9702392D0 (en) 1997-02-06 1997-03-26 Boots Co Plc Therapeutic agents
US6210710B1 (en) * 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
WO1999007342A1 (en) * 1997-08-11 1999-02-18 Alza Corporation Prolonged release active agent dosage form adapted for gastric retention
NZ333474A (en) * 1998-01-02 1999-06-29 Mcneil Ppc Inc A chewable tablet containing ibuprofen, fumaric acid and a non hydrocolloid binder e.g. a wax or a fat
US20030153623A1 (en) * 1998-07-22 2003-08-14 Yamanouchi Pharmaceutical Co., Ltd. Solid preparation containing sparingly soluble NSAIDs
IT1301966B1 (it) * 1998-07-30 2000-07-20 Zambon Spa Composizioni farmaceutiche ad attivita' analgesica
GB9816899D0 (en) 1998-08-05 1998-09-30 Boots Co Plc Therapeutic agents
US5997905A (en) * 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
EP1161941A4 (en) 1999-03-15 2002-08-28 Kaken Pharma Co Ltd FAST DELITING TABLETS AND MANUFACTURING METHOD
WO2001022939A1 (en) * 1999-09-29 2001-04-05 Fmc Corporation Hydrolyzed cellulose granulations of salts of drugs
DE10001166A1 (de) * 2000-01-13 2001-07-19 Merckle Gmbh Anellierte Pyrrolverbindungen, diese enthaltende pharmazeutische Mittel und deren Verwendung
DE10003757A1 (de) * 2000-01-28 2001-08-02 Knoll Ag Ibuprofen-Wirkstoffzubereitung
US6623756B1 (en) * 2000-04-27 2003-09-23 Noveon Ip Holdings Corp. Directly compressed solid dosage articles
US20030175349A1 (en) 2001-01-30 2003-09-18 Council Of Scientific And Industrial Research Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient
GB0108930D0 (en) * 2001-04-10 2001-05-30 Boots Co Plc Therapeutic agents
US20030026834A1 (en) * 2001-04-10 2003-02-06 Fahkreddin Jamali NSAIDs composition containing tartaric acid
GB0113841D0 (en) * 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents
US6673369B2 (en) * 2001-08-29 2004-01-06 Ranbaxy Laboratories Limited Controlled release formulation
US6592901B2 (en) * 2001-10-15 2003-07-15 Hercules Incorporated Highly compressible ethylcellulose for tableting
US20040047904A1 (en) * 2001-11-13 2004-03-11 Motohiro Ohta Amino acid-containing tablets quickly disintegrating in the oral cavity and process for producing the same
US6866070B2 (en) * 2002-08-08 2005-03-15 Glen Ellyn Industries Llc Bag insert and support
US20040122048A1 (en) 2002-10-11 2004-06-24 Wyeth Holdings Corporation Stabilized pharmaceutical composition containing basic excipients
CH693586A8 (de) * 2002-10-14 2003-12-15 Roche Consumer Health Ag Darreichungsform von Ibuprofen-Natrium.
US20040121010A1 (en) 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US20040096497A1 (en) * 2002-11-19 2004-05-20 Ponder Garratt W. Methods of providing controlled-release pharmaceutical compositions and controlled-release pharmaceutical compositions
JP2004175690A (ja) * 2002-11-25 2004-06-24 Shionogi & Co Ltd 粒子径の異なる糖質を配合した製剤
EP1575584A4 (en) * 2002-11-29 2006-02-01 Forest Laboratories METHOD FOR THE TREATMENT OF ACUTE CHARACTERIZATION BY UNIFORM FORMING WITH IBUPROFEN AND OXYCODON
WO2005000237A2 (en) * 2003-06-25 2005-01-06 University Of Tennessee Research Foundation Granules containing biologically active substances
US20060068009A1 (en) * 2004-09-30 2006-03-30 Scolr Pharma, Inc. Modified release ibuprofen dosage form
US20070077297A1 (en) * 2004-09-30 2007-04-05 Scolr Pharma, Inc. Modified release ibuprofen dosage form
JP5026675B2 (ja) 2005-03-08 2012-09-12 洋文 竹内 錠剤、およびその製造方法
DE102005049001A1 (de) 2005-10-11 2007-04-12 Basf Ag Verfahren zur Herstellung von direkttablettierbaren Ibuprofen-Formulierungen
FI20060501L (fi) 2006-05-22 2007-11-23 Biohit Oyj Koostumus ja menetelmä asetaldehydin sitomiseksi vatsassa

Also Published As

Publication number Publication date
TW200831135A (en) 2008-08-01
BRPI0717916A8 (pt) 2016-05-10
CA2670887A1 (en) 2008-06-12
US9028869B2 (en) 2015-05-12
US20070077297A1 (en) 2007-04-05
CO6190599A2 (es) 2010-08-19
WO2008069941A3 (en) 2008-09-12
US9730895B2 (en) 2017-08-15
US20100143466A1 (en) 2010-06-10
CN101588793B (zh) 2012-12-19
CN101588793A (zh) 2009-11-25
WO2008069941A2 (en) 2008-06-12
MX2009005958A (es) 2010-12-20
KR20090086468A (ko) 2009-08-12
IL199191A0 (en) 2010-03-28
US20150196491A1 (en) 2015-07-16
JP2010511614A (ja) 2010-04-15
CN101594853A (zh) 2009-12-02
BRPI0717916A2 (pt) 2014-08-26
EP2099433A2 (en) 2009-09-16
AU2007328393A1 (en) 2008-06-12

Similar Documents

Publication Publication Date Title
ZA200904436B (en) Modified release ibuprofen solid oral dosage form
IL182144A0 (en) Modified release ibuprofen dosage form
PL2457563T3 (pl) Stałe postacie dawkowania o zmodyfikowanym uwalnianiu rzędu zerowego
PT2077729E (pt) Formas orais probióticas
EP2011482A4 (en) SOLID PREPARATION FOR ORAL APPLICATION
ZA200810164B (en) Sustained release pharmaceutical dosage form containing phenylphrine
IL206159A0 (en) Oral pharmaceutical dosage forms
ME01550B (me) Farmaceutski dozni oblici
PL1935395T3 (pl) Doustna kompozycja
HK1125295A1 (zh) 基於微片的藥物製劑
EP2112925A4 (en) SOLID PHARMACEUTICAL DOSAGE FORMULATIONS
HK1154484A1 (zh) 口服組合物
IL194366A0 (en) Solid dosage formulations
GB0710439D0 (en) Oral dosage form
IL204528A (en) Pharmaceutical dosage forms for immediate sustained release of metadoxin
EP2226071A4 (en) COMPOSITIONS FOR ORAL ADMINISTRATION
HK1206267A1 (zh) 穩定化的吡鉑口服劑型
PL2002828T3 (pl) Stały preparat farmaceutyczny
GB0616794D0 (en) Solid dosage form
IL198760A0 (en) Oral formulations
IL198160A0 (en) Pharmaceutical formulations
GB0822124D0 (en) Oral dosage form
ZA200702694B (en) Modified release ibuprofen dosage form
HK1115054A1 (en) Preparation for oral administration
PL1915137T3 (pl) Preparat doustny o kontrolowanym uwalnianiu